Q2 2025 Cytosorbents Corp Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: $0.8932 (-0.98%)

Transcript 10-Q

Key Points

Positve

CytoSorbents Corp (CTSO) reported a 9% year-over-year increase in product sales for Q2 2025, with a 4% increase on a constant currency basis.
The company's German commercial team reorganization led to a 22% growth year-over-year and sequentially, indicating successful strategic realignment.
Gross margin performance remained solid at approximately 71%, demonstrating strong financial management.
CytoSorbents Corp (CTSO) is actively preparing for a potential North American commercial launch of DrugSorb ATR, with regulatory decisions expected by the end of 2025.
The company is making significant progress in addressing sepsis and septic shock, with new publications supporting the efficacy of CytoSorb in improving patient outcomes.

Negative

CytoSorbents Corp (CTSO) faced regulatory challenges, with both the FDA and Health Canada issuing denials for DrugSorb ATR, requiring an appeals process.
Operating expenses increased by 3% year-over-year due to unique charges, including costs associated with regulatory appeals and commercial restructuring.
The company's gross margin decreased slightly from 73.5% in Q2 2024 to 70.9% in Q2 2025, partly due to inventory write-offs.
Despite progress, the company is still working towards achieving near break-even for its core business by the end of 2025.
The regulatory approval process for DrugSorb ATR in North America remains uncertain, with potential outcomes including outright denial.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CTSO.OQ - Cytosorbents Corp
Q2 2025 Cytosorbents Corp Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day ladies and gentlemen, and welcome to the Q2 2025 earnings conference call for CIO servants score. At this time, all answers are in this synonymous.

Following the presentation, we'll conduct a question and answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. This call is being recorded on Wednesday.

Please, sorry, I would like to turn the conference over to Adana Alexander, investor relations consultant. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Sergio, and good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.